|
| 36382533 | Differential responses to taxanes and PARP inhibitors in ATM-Â versus BRCA2-mutated metastatic castrate-resistant prostate cancer. | Prostate | 2023 |
| 37497748 | Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out? | Curr Opin Urol | 2023 |
| 37150667 | Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy. | Clin Genitourin Cancer | 2023 |
| 37344281 | Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. | Clin Genitourin Cancer | 2023 |
| 37207301 | Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair. | Am Soc Clin Oncol Educ Book | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36623239 | Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. | JCO Precis Oncol | 2023 |
| 36609003 | Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. | Eur Urol | 2023 |
| 36710146 | A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer. | Clin Genitourin Cancer | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36564459 | Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2023 |
| 36414905 | ASO Visual Abstract: Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers. | Ann Surg Oncol | 2023 |
| 36335273 | Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers. | Ann Surg Oncol | 2023 |
| 35998004 | Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma. | Cancer Immunol Immunother | 2023 |
| 34775478 | Disparities in germline testing among racial minorities with prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 35710085 | Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. | Contemp Clin Trials | 2022 |
| 35834759 | <i>BRCA2</i> Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series. | JCO Precis Oncol | 2022 |
| 35394343 | A Patient-Centered Approach to Research Prioritization in Prostate Cancer. | J Urol | 2022 |
| 35657157 | Germline genetics of prostate cancer. | Prostate | 2022 |
| 36509074 | NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. | J Natl Compr Canc Netw | 2022 |
| 34863587 | Inherited TP53 Variants and Risk of Prostate Cancer. | Eur Urol | 2022 |
| 33151258 | Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. | JAMA Oncol | 2021 |
| 33792945 | Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. | Prostate | 2021 |
| 33545689 | NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. | J Natl Compr Canc Netw | 2021 |
| 33551249 | Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. | Urol Oncol | 2021 |
| 34407973 | Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2021 |
| 34669358 | Germline Testing in Prostate Cancer: When and Who to Test. | Oncology (Williston Park) | 2021 |
| 34516663 | Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. | Prostate | 2021 |
| 34778690 | Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer. | JCO Precis Oncol | 2021 |
| 34651094 | Adopting Consensus Terms for Testing in Precision Medicine. | JCO Precis Oncol | 2021 |
| 34210490 | Genetic Contribution to Metastatic Prostate Cancer. | Urol Clin North Am | 2021 |
| 34057231 | Barriers and facilitators of germline genetic evaluation for prostate cancer. | Prostate | 2021 |
| 33972096 | Molecular Subtyping in the Neoadjuvant Setting in Prostate Cancer: Envisioning the Possibilities. | Eur Urol | 2021 |
| 33160889 | Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. | Clin Genitourin Cancer | 2021 |
| 31630993 | Ethnic disparities among men with prostate cancer undergoing germline testing. | Urol Oncol | 2020 |
| 34109262 | Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes. | Bladder Cancer | 2020 |
| 32055002 | Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. | Prostate Cancer Prostatic Dis | 2020 |
| 31974718 | Genetic Testing in Prostate Cancer. | Curr Oncol Rep | 2020 |
| 31734020 | Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. | Urol Oncol | 2020 |
| 32886903 | Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies. | J Natl Compr Canc Netw | 2020 |
| 32997692 | Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. | PLoS One | 2020 |
| 32986533 | Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. | JCO Oncol Pract | 2020 |
| 32897829 | Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. | J Clin Oncol | 2020 |
| 32234758 | Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity. | Clin Cancer Res | 2020 |
| 32516092 | Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. | J Clin Oncol | 2020 |
| 32453797 | Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. | PLoS One | 2020 |
| 29020856 | Hepatitis C infection and chemotherapy toxicity. | J Oncol Pharm Pract | 2019 |
| 31629426 | Current recommendations for prostate cancer genetic testing: NCCN prostate guideline. | Can J Urol | 2019 |
| 31629420 | Germline contributions to metastatic prostate cancer. | Can J Urol | 2019 |
| 31361600 | Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. | J Clin Invest | 2019 |